By Grace TurnerEli Lilly Q3 revenue climbed 39% year over year to reach $24.4 billion, powered by expanding global prescriptions for metabolic treatments Mounjaro and Zepbound. Following the strong third-quarter performance announced on October 29, the Indianapolis drugmaker raised the midpoint of its full-year 2026 sales outlook by $5.5 billion.
The company now projects full-year 2026 revenue between $91.0 billion and $92.0 billion. That upward revision reflects sustained prescription momentum across both diabetes and chronic weight management markets during the July-through-September period.
Third-quarter results also included approximately $900 million in milestone benefits tied to Jardiance and favorable adjustments to rebate and discount estimates. Investors tracking business performance across the healthcare sector noted that prescription volume gains more than offset lower realized prices.
Mounjaro and Zepbound Drive Global Volume Expansion
Worldwide sales of Mounjaro surged 65% in the third quarter to $10.7 billion as international launches and broader formulary coverage expanded patient access. In the United States, Zepbound generated $5.3 billion in quarterly revenue, marking a 48% increase compared with the prior-year period.
Chair and Chief Executive Officer David A. Ricks stated that the third-quarter performance exceeded internal expectations and enabled management to lift its annual guidance. Expanded manufacturing capacity allowed the company to meet rising pharmacy orders across North America, Europe, and key Asian markets.
Total worldwide shipment volume across the product portfolio rose 53% during the quarter, while average realized prices declined 15%. In the domestic market alone, prescription volume grew 41% even as net realized prices dipped 7% due to channel mix and rebate dynamics.
Pricing Agreements and Regulatory Considerations
Lower net realized prices reflect ongoing negotiations with commercial pharmacy benefit managers and government healthcare programs. Management highlighted the implementation of its voluntary agreement with the U.S. government regarding pharmaceutical pricing and patient access as an important operational factor.
Federal and state policy initiatives aimed at prescription drug reimbursement remain key variables for fourth-quarter and 2027 financial planning. Company filings noted that shifts in public reimbursement rules or commercial formulary tiers could influence future margin trajectories.
To counter price compression, the manufacturer continues investing billions of dollars into new active pharmaceutical ingredient facilities and automated fill-finish lines. Securing reliable supply chains for injectable pens and oral small-molecule candidates remains central to its multi-year capital allocation strategy.
Analysts expect metabolic therapies to remain the primary growth engine heading into the final months of 2026. With full-year revenue now projected to top $91 billion, operational execution will center on balancing high-volume distribution against evolving global pricing frameworks.
Manufacturing Scale and Global Metabolic Market Outlook
Expanding production output remains the central operational priority as prescription demand continues to outpace pharmacy inventory across several international regions. New parenteral manufacturing lines in Indiana, North Carolina, and Europe have steadily increased monthly syringe and auto-injector availability throughout 2026.
Clinical trial readouts for next-generation oral and injectable incretin candidates also support long-term revenue visibility beyond the current commercial lineup. Healthcare economists note that broader insurance coverage for cardiovascular and sleep apnea indications is expanding the eligible patient population across employer-sponsored health plans, positioning the drugmaker for sustained double-digit volume growth into 2027.
Financial analysts noted that operating leverage from existing sales infrastructure allowed research and development investments to grow without diluting quarterly net margins. Sustained demand across both commercial and government channels reinforces long-term cash flow stability.
